Exa-cel
Phase 3RecruitingInterest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Sickle Cell Disease
Conditions
Sickle Cell Disease
Trial Timeline
Jul 31, 2027 → Dec 31, 2033
NCT ID
NCT05951205About Exa-cel
Exa-cel is a phase 3 stage product being developed by Vertex Pharmaceuticals for Sickle Cell Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05951205. Target conditions include Sickle Cell Disease.
What happened to similar drugs?
3 of 20 similar drugs in Sickle Cell Disease were approved
Approved (3) Terminated (10) Active (8)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05951205 | Phase 3 | Recruiting |
Competing Products
20 competing products in Sickle Cell Disease